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fibrillation (VT/VF), post-operative stroke (CVA), and post-operative myocardial infarction
(MI).
Methods: We conducted a meta-analysis to assess the effect of peri-operative amio-
darone on the incidence of morbidity and mortality. MEDLINE, CINAHL, Cochrane Cen-
tral Register of Controlled Trials, and EMBASE databases were searched through 5/2003
with the terms atrial fibrillation, amiodarone and surgery. Inclusion criteria were random-
ized controlled double-blind study design and primary outcome designated as incidence
of AF/AFL. AF/AFL, VT/VF, CVA, MI, and mortality data were pooled using the DerSimo-
nian-Laird method with a random effects model. Trial heterogeneity was assessed via the
Woolf Q statistic, and publication bias was assessed with Kendall’s test on standardized
effect vs. variance.
Results: Eight randomized controlled double blind placebo trials with a total of 1,527
patients were included in our analysis of the incidence of AF/AFL and mortality. Of these,
six trials (1,184 patients) reported data on VT/VF, CVA, and MI. Heterogeneity and publi-
cation bias were not detected. Amiodarone significantly decreased the incidence of AF/
AFL [odds ratio 0.539, 95% CI (0.428, 0.678), P<0.0001], VT/VF [odds ratio 0.308, 95%
CI (0.164, 0.579), P=0.0003], and CVA [odds ratio 0.434, 95% CI (0.203, 0.929),
P=0.0315], when compared to placebo. Amiodarone did not significantly decrease the
incidence of MI [odds ratio 0.821, 95% CI (0.265, 2.543), P=0.732] and had no impact on
mortality [odds ratio 1.043, 95% CI (0.460, 2.370), P=0.919].
Conclusion: Amiodarone significantly reduced not only the incidence of AF/AFL, but also
of VT/VF and CVA. This study has important clinical implications and illustrates the need
for future prospective studies adequately powered to detect reductions in cardiovascular
morbidity and mortality.
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1172-67 Use of Administrative Databases May Lead to Incorrect 
Estimates of the Effects of Nonaspirin Nonsteroidal 
Anti-Inflammatory Drugs on MIyocardial Infarction Risk
Stephen E. Kimmel, Jesse A. Berlin, Jane Jaskowiak, Lori Kishel, Brian L. Strom, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Background: Studies using administrative, prescription databases have generally shown
no effect of most nonselective non-aspirin nonsteroidal anti-inflammatory drugs (NAN-
SAIDs) on cardiovascular risk. We analyzed data from a study that specifically addressed
the biases inherent in using prescription databases to determine the effect of these
potential biases.
Methods: In our case-control study of NANSAIDs and first MI, we determined the odds
ratio for prescription (Rx) NANSAIDs versus non-users on MI risk as follows: (1) Replicat-
ing administrative database studies by: including over-the-counter (OTC) NANSAID
users as “non-users,” not excluding aspirin (ASA) users, and not adjusting for confound-
ers typically unavailable in administrative databases (smoking, family history, body mass
index, education, and physical activity). (2) Analysis #1 after removing OTC NANSAIDs
from the “non-user” category. (3) Analysis #2, adding adjustment for the confounders
listed above. (4) Analysis #3 plus excluding ASA users.
Results: OTC NANSAIDs accounted for 79% of all NANSAID use. ASA use was 28%.
Replication of administrative database analyses led to a null result (table). As we
removed each potential bias from our study, the OR moved further from 1.0 and indicated
a significant benefit of NANSAIDS in the fully adjusted analysis (#4).
Conclusion: The inability to measure OTC NANSAIDs, exclude ASA users, and adjust
for confounding may bias studies of prescription NANSAIDs and MI towards showing no
effect.
1172-68 Does Statin Therapy Reduce Contrast-Induced 
Nephropathy? An Analysis From a Large Regional 
Registry of Contemporary Percutaneous Interventions
Sanjaya Khanal, Nizar Attallah, Dean E. Smith, Eva Kline-Rogers, David Share, Michael 
J. O'Donnell, Mauro Moscucci, Henry Ford Hopsital, Detroit, MI, University of Michigan, 
Ann Arbor, MI
Background: Intravascular administration of contrast media can have nephrotoxic
effects particularly in patients with baseline renal insufficiency. Along with lowering serum
cholesterol, statins have pleiotropic effects in the vasculature. It is unclear whether statin
use has a protective effect against contrast-induced nephropathy (CN).
Methods: We evaluated 29,409 patients who had both baseline pre-procedure and peak
post-procedure serum creatinine measured at the time of their percutaneous coronary
intervention (PCI). Baseline demographics and creatinine profile before and after the pro-
cedure were compared between patients who received pre-procedure statins and those
who did not. CN was defined as increase in serum creatinine of >0.5 mg/dl.
Results: Baseline clinical characteristics were similar between the 2 groups (table).
When compared to patients who did not receive pre-procedure statins, patients on pre-
procedure statins had a lower incidence of CN (4.9 vs. 6.8, p<0.0001) and a trend
towards reducion of nephropathy requiring dialysis (0.4 vs. 0.6, p=0.07). After adjust-
ments for comorbidities, pre-procedure statin use was associated with a significant
reduction in CN (OR 0.81, 95% CI 0.72-0.92, p=0.0009).
Conclusions: Pre-procedure statin use is associated with significant reduction in CN
after contemporary PCI.
1172-69 Early Use of Small Molecule Platelet Glycoprotein IIb/IIIa 
Inhibitors for All Acute Coronary Syndrome Patients Is 
Superior to Selective Use of Abciximab for Only Those 
Requiring Percutaneous Coronary Interventions
Ruchira Glaser, Henry Glick, Howard C. Herrmann, Stephen E. Kimmel, University of 
Pennsylvania, Philadelphia, PA
Background: Selective use of medication may be important when several competing
therapies are available. Tirofiban and eptifibatide are small molecule platelet GP IIb/IIIa
inhibitors with benefit in acute coronary syndromes (ACS), but may not be as effective as
abciximab during percutaneous coronary intervention (PCI). However, abciximab does
not have proven efficacy in medical management of patients with ACS. No prior study
has attempted to balance the competing benefits of a strategy of giving all ACS patients a
small molecule versus a strategy of using abciximab only if a patient undergoes PCI. 
Methods: A decision analysis examined two treatment options and estimated under
what conditions one strategy was superior to another. The two strategies were (1) treat
all ACS patients initially with a small molecule GP IIb/IIIa inhibitor or (2) selectively use
abciximab only in ACS patients who ultimately undergo PCI. Sensitivity analyses were
performed over a wide range of assumptions. The primary outcome was life expectancy,
and cost effectiveness and bleeding were a secondary outcomes.
Results: The strategy of general use of a small molecule GP IIb/IIIa inhibitor on presen-
tation with ACS resulted in an average life expectancy of 15.93 years, compared with
15.71 years for selective use (life years savings of 0.22 years). The superiority of the gen-
eral use strategy persisted over all but extremes in sensitivity analyses. Preliminary cost
analyses showed general use as economically attractive, with cost per life year of less
than $50,000 over a wide range of assumptions. There was a similar likelihood of major
bleeding for patients with general use v. selective (6.5% v 6.1%).
Conclusion: General use of early GP IIb/IIIa inhibition in all patients presenting with
ACS leads to better outcomes than selective use. A selective use strategy may be supe-
rior only if a patient is extremely likely to undergo PCI (over 90%)or there is virtually no
reduction of events in medically managed patients receiving GP IIb/IIIa inhibition. When
faced with these competing strategies, the clinician should consider the significant, cost
effective benefits to general use of small molecule platelet GP IIb/IIIa inhibitors in ACS.
1172-70 Tolerability, Safety, and Efficacy of Beta-Blockade in 
Black Patients With Heart Failure in the Community 
Setting: Insights From a Large Prospective Beta-
Blocker Registry
William T. Abraham, Barry M. Massie, Mary Ann Lukas, Sandra R. Lottes, Jeanenne J. 
Nelson, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Conflicting data exist regarding the tolerability and efficacy of beta-block-
ade in Black patients with heart failure (HF). In randomized controlled trials bucindolol
appeared to worsen clinical outcome in Blacks while carvedilol apparently improved out-
come comparably to White patients.
Methods: The Coreg Heart Failure Registry (COHERE) prospectively evaluated the
early and 1-yr tolerability, safety, and efficacy of carvedilol in 4,280 HF patients treated in
the community setting.
Results: Prior to initiation of carvedilol, Black patients (n=523) differed from White
patients (n=3,433) in demonstrating more severe symptoms (NYHA Class III/IV, 44.3% vs
35.3%, p<0.001), more diabetes (37.1% vs 30.3%, p=0.002), less history of ischemic
Effects of Adjustment
Analysis
(see text)
Odds Ratio (95% CI)
#1 Replicating Administrative Database Analysis 1.0 (0.7-1.3)
#2 0.9 (0.7-1.1)
#3 0.8 (0.6-1.0)
#4 - Fully adjusted 0.7 (0.5-0.9)
Statin use and CN
Pre-statins No Pre-statins
Variable N=11,017 N=18,392 p-value
Age (mean (SD)), yrs 63.6 63.6 0.78
Female (%) 33.9 35.4 0.008
Baseline Creatinine (mean mg/dl) 1.2 1.2 0.50
Percent with Baseline Creatinine 1.5+mg/dl 12.9 12.6 0.54
Percent with Baseline Creatinine 2.0+mg/dl 4.8 5.0 0.42
Peak Creatinine (mean mg/dl) 1.3 1.3 0.30
Peak Creatinine 1.5+mg/dl 14.5 15.8 0.003
Peak Creatinine 2.0+mg/dl 6.6 7.9 <0.0001
Renal Failure Requiring Dialysis 0.4 0.6 0.07
Contrast Nephropathy 4.9 6.8 <0.0001
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heart disease (prior myocardial infarction, 22.9% vs 44.2%, p<0.001), and more history
of hypertension (79.2% vs 55.1%, p<0.001). Slightly higher resting heart rates and blood
pressures were also observed in Blacks. While the reported HF etiology was predomi-
nantly hypertensive in Blacks and ischemic in Whites, the proportion of patients with pre-
served left ventricular function did not differ between the two groups, as 16.5% of Whites
and 16.7% of Blacks had left ventricular ejection fractions >40% (p=0.93). Physician
assessment of carvedilol titration demonstrated excellent tolerability in both groups, with
no problem or mildly difficult assessments recorded for 86.2% of Black patients vs 81.8%
of White patients, p=0.02. There was no difference in distribution of carvedilol dose by
race, with most patients achieving a dose of at least 6.25 mg bid. Compared to the 12
months prior to carvedilol initiation, hospitalization rates for all-causes, cardiovascular
reasons other than HF, and HF were reduced in both groups during carvedilol treatment.
The incidence of death per 1,000 person-years was similar in Blacks (71.0) and Whites
(73.6), and the hazard ratio was 1.01 (95% CI 0.68 to 1.49; p=0.96).
Conclusions: In the community setting of COHERE, carvedilol was well tolerated in
Blacks who, despite different baseline characteristics and risk factors for HF, also demon-
strated safety and efficacy comparable to that seen in White patients.
1172-71 Practical Predictors of Clinical Outcomes in Patients 
Initiating Beta-Blockers for Heart Failure: Findings of a 
Community-Based Registry
Barry Greenberg, Sandra R. Lottes, Jeanenne J. Nelson, Mary Ann Lukas, Michael B. 
Fowler, Barry M. Massie, William T. Abraham, Edward M. Gilbert, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Increased morbidity and mortality in heart failure (HF) patients has been
related to risk factors derived from populations in clinical trials, at hospital discharge, or in
localized geographic/socioeconomic strata, and were identified before wide use of beta-
blockers for HF.
Methods: The Coreg Heart Failure Registry (COHERE) observed 4,280 unselected HF
patients during 1-yr follow-up after initiating carvedilol in a community setting. Patients
entered the registry regardless of ejection fraction (EF). Significant risk factors for the
composite of death, hospitalization for HF and hospitalization for cardiovascular (CV)
reasons other than HF were identified by age-, sex-, and race-adjusted analyses. Inde-
pendent risk factors were identified from a multivariable analysis adjusted for all factors
simultaneously.
Results: Over this period 7% of patients died, 11% were hospitalized for HF, 12% were
hospitalized for other CV reasons, and 27% had any of these events. Key findings of the
multivariate analysis are shown in the table. 
Although EF and blood pressure were significant predictors when adjusted for age, sex,
and race, the relationship did not persist when simultaneously adjusted for other co-vari-
ables.
Conclusions: Simple historical information identifies community HF patients at
increased risk for death or hospitalization in the year after initiating carvedilol. In this pop-
ulation not selected by EF, these historical factors appear to better predict risk than did
EF.
1172-72 Combination Evidence-Based Therapy Improves 
Survival After Percutaneous Coronary Intervention
Brahmajee K. Nallamothu, Debabrata Mukherjee, Stanley Chetcuti, Paul M. Grossman, 
Rupal Dumasia, Eva Kline-Rogers, Bertram Pitt, Kim A. Eagle, Mauro Moscucci, 
University of Michigan, Ann Arbor, MI
Introduction: The impact of combination "evidence-based" therapy (ASA, beta-blockers,
ace inhibitors, and statin use) on long-term survival of patients undergoing percutaneous
coronary intervention (PCI) is uncertain.
Hypothesis: We hypothesized that post-PCI patients with higher rates of use of evi-
dence-based therapy would have lower mortality rates.
Methods: We collected clinical and angiographic data on consecutive PCIs from July
1997 to October 2001. An additive evidence-based therapy score (0-4) was calculated by
applying 1 point each to hospital discharge on ASA, beta-blockers, ace inhibitors and
statins. Follow-up long-term survival was obtained by telephone contact and/or searching
the Social Security Death Index. Using a Cox proportional hazards model, we assessed
the impact of the score on survival after adjusting for age, sex, cardiac risk factors (e.g.,
diabetes(DM), hypertension, congestive heart failure, ejection fraction, extent of coronary
disease, renal insufficiency, hx of bypass surgery/PCI/acute myocardial infarction(MI),
clinical priority and procedural factors (e.g., stent, gIIb/IIIa use).
Results: 2311 patients underwent 3231 PCIs with a mean-follow-up of 344 +/- 225 days.
Mean age was 63 +/- 12 years; 752 (33%) were women, 609 (26%) had DM, 487 (19%)
had recent MI. Most (78%) received stents. 211 (9%) patients were discharged on 0-1
evidence-based therapies (i.e., score of 0-1) and 570 (25%) were discharged on all 4 evi-
dence-based therapies. After multivariate adjustment, the evidence-based therapy score
remained an independent predictor of improved survival (HR per 1 unit increase in evi-
dence-based therapy score, 0.78; 95% ci, 0.66-0.92; p=0.003). Other significant factors
included: advanced age, congestive heart failure, ejection fraction, left main disease,
multivessel PCI, renal insufficiency, and post-PCI QWMI.
Conclusion: The use of combination evidence-based therapy as assessed by an addi-
tive score is independently associated with improved survival after PCI. Evidence-based
therapy use should be strongly encouraged and implemented in these patients.
1172-73 First Postoperative Day Prognosis Score in Patients 
Undergoing Cardiac Surgery Based on Pre-, Peri-, and 
Postoperative Variables
Renato V. Gomes, Alexandre Rouge, Fernando Aranha, Marco A. Fernandes, Pedro 
Nogueira, Jorge Sabino, Luiz A. Campos, Bernardo Tura, Hans F. Dohmann, Hans J. 
Dohmann, Hospital Pro-cardiaco, Rio de Janeiro, Brazil, Instituto nacional de Cardiologia 
de Laranjeiras, Rio de Janeiro, Brazil
Background: We have several prognosis models for heart surgery (HS). However, these
scores were based on preoperative variables, our model have used both, preoperative
and first postoperative day (FPOD) . Objectives: To create a predictive score of in-hospi-
tal mortality in patients (pts) undergoing HS and admitted to a public and private surgical
intensive care unit (SICU), analyzing pre-, perioperative and FPOD variables. Case
series and methods: Classical cohort of data (1,458 pts) consecutively collected from
June 2000 to February 2003. All 46 variables were previously defined according to the
major prognostic index found in the literature. The statistical analysis comprised: univari-
ate analysis with the chi-square test, Student t test, Mann-Whitney and Pearson tests, fol-
lowed by logistic regression and stepwise (likelihood ratio), with the linear trend test and
ROC curve. Results: The score , shown in the attached table, provides the following risk
prediction: 0 to 4 – low risk; 5 to 9 – medium; and 10 to 14 – high. The results had signif-
icance (p<0.0001) and linear trend (p<0,0001). The area under the ROC curve was 0.84.
Conclusions: The score shows the strength of the variables on the FPOD, such as worse
PO2/ FiO2 < 100, epinephrine > 0,1 or norepinephrine > 0,1, and mechanical ventilation
duration > 12 h, probably related to perioperative factors, such as type of anesthesia,
host response, hemodynamic profile, use or nonuse of corticosteroids.
1172-74 Pulmonary Hypertension Is Strongly Associated With 
Mortality in Sickle Cell Disease: Comparison of 
Echocardiographic Outcome Predictors
Yukitaka Shizukuda, Vandana Sachdev, Inez Ernst, James S. Nichols, Maria Jison, 
Bernice Brown, William Blackwelder, Griffin P. Rodgers, Oswaldo Castro, Frederick P. 
Ognibene, Jonathan P. Plehn, Mark T. Gladwin, National Heart, Lung, and Blood 
Institute, Bethesda, MD, Howard University, Washington, DC, DC
Background: The development of pulmonary hypertension (PH) has been reported in
most hemolytic anemias and preliminary reports have suggested its prognostic value in
sickle cell disease (SSD). We, therefore, assessed the predictive values of transthoracic
Variable Odds 
Ratio
95% Confidence 
Limits
P
NYHA class (IV vs I) 3.56 2.23 - 5.68 <0.001
NYHA class (III vs I) 2.85 2.08 - 3.91 <0.001
HF Hospitalization prior yr 1.92 1.63 - 2.25 <0.001
NYHA class (II vs I) 1.66 1.22 - 2.26 <0.001
History of angina 1.38 1.17 - 1.63 <0.001
HF duration (> 2yr vs < 6 mos) 1.28 1.06 - 1.54 0.009
History of diabetes 1.22 1.04 - 1.43 0.013
History of acute MI 1.20 1.01 - 1.43 0.039
MD (non-cardiologist vs cardiologist) 1.12 0.94 - 1.33 0.216
Sex (males vs females) 1.05 0.89 - 1.23 0.555
Age ( per 1 yr increase) 1.01 1.00 - 1.01 0.171
Race (Black vs Caucasian) 1.00 0.78 - 1.28 0.992
MD (yrs since graduation 19-24 vs <13 yr) 0.82 0.68 - 1.00 0.055
MD (yrs since graduation 13-18 vs <13 yr) 0.76 0.62 - 0.94 0.011
Insurance (commercial vs Medicare/Medicaid) 0.76 0.60 - 0.95 0.017
MD (yrs since graduation >24 vs <13 yr) 0.71 0.58 - 0.87 <0.001
HF cause (Idiopathic vs CAD) 0.71 0.55 - 0.91 0.007
HF cause (HTN vs CAD) 0.69 0.53 - 0.89 0.004
CAD = coronary artery disease; HTN = hypertension
95% CI for OR
Characteristics OR Lower Upper Score
Age 64 to 74years 2,05 1,16 3,63 +1
Age >75 years 4.79 2,60 8,83 +2
Left atrium>45mm 2,58 1,53 4,37 +1
Creatinine>2mg/dl 4,84 1,87 12,48 +2
Extracorporeal circulation>180min 4,93 1,99 12,18 +2
Worse FPOD PO2/FiO2 < 100 9,47 3,18 28,23 +3
FPOD Epinephrine > 0.1 or Nor > 0.1 mcg/kg/min 6,78 3,99 11,53 +3
FPOD duration of mechanical ventilation > 12 h 2,24 1,34 3,72 +1
